GlassScriptPhysician profile
Aaron M Murfin
NPI 1821646092
$2,179.73
in general payments reported to CMS, 2019-2025
27 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $539 · 2023: $616 · 2024: $436 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.20 | 2021-2025 | |
| Astellas Pharma US INC | $167.09 | 2021-2023 | Veozah |
| Pfizer INC. | $146.71 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $133.10 | 2021-2023 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $99.90 | 2022-2023 | |
| Dexcom, INC. | $97.70 | 2022-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $88.61 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $86.06 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $73.00 | 2021-2023 | Pediarix, Bexsero, Trelegy Ellipta |
| Lucid Diagnostics INC. | $71.65 | 2023 | |
| Xeris Pharmaceuticals, INC. | $62.71 | 2022-2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $62.25 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.12 | 2021-2022 | |
| Grifols USA, LLC | $61.69 | 2022-2024 | Prolastin-C Liquid |
| Sk Life Science, INC. | $49.53 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $48.33 | 2024-2025 | |
| Lundbeck LLC | $46.10 | 2024-2025 | Vyepti |
| Merck Sharp & Dohme LLC | $43.28 | 2021-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Otsuka America Pharmaceutical, INC. | $43.18 | 2024 | Rexulti, Abilify Asimtufii |
| Acadia Pharmaceuticals INC | $42.18 | 2024-2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $40.85 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $35.01 | 2025 | Motpoly Xr |
| Teva Pharmaceuticals USA, INC. | $31.65 | 2025 | Austedo Xr |
| Nestle Healthcare Nutrition INC. | $27.93 | 2021 | |
| Cycle Pharmaceuticals INC | $14.76 | 2024 | Tascenso Odt |
| Bayer Healthcare Pharmaceuticals INC. | $14.44 | 2024 | |
| Endo Pharmaceuticals INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Murfin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.